RGC-specific reversal of lipid peroxidation drives neuroprotection and vision restoration in optic nerve stroke by targeting GPX4

The human eye is a marvel of biological engineering, yet it operates in a state of constant, high-stakes tension. The retina, the light-sensitive tissue at the back of the eye, and the optic nerve, the cable that carries visual signals to the brain, are packed with energy-hungry cells and membranes rich in fats. These fats are essential for the cells to function, but they are also fragile. When blood flow is interrupted, a condition known as ischemia, the delicate balance of oxygen and energy shifts. This disruption causes the fats in the cell membranes to react with oxygen in a destructive process called lipid peroxidation. Think of this process like the rusting of a metal pipe: the material itself begins to corrode from the inside out, weakening the structure until it fails. For decades, doctors have known that a sudden blockage of blood to the optic nerve causes a devastating condition called non-arteritic anterior ischemic optic neuropathy, or NAION, which strikes older adults with sudden, painless vision loss. While the initial cause is a lack of blood, the reason why the nerve cells die permanently and why no current treatment can stop the damage has remained a mystery.

A team of researchers at Stanford University has now identified the specific mechanism that turns this temporary blood shortage into permanent blindness. They discovered that the real killer in NAION is not just the lack of oxygen, but the subsequent buildup of toxic byproducts from those damaged fats. In a study combining analysis of human tissue with rigorous experiments in mice, the scientists found that when the optic nerve is starved of blood, the fats in the membranes of the retinal ganglion cells—the neurons responsible for vision—undergo rapid oxidation. This process generates harmful chemicals that destroy the cells from within. The researchers showed that this damage is driven by a lack of a specific protective enzyme called glutathione peroxidase 4, or GPX4. This enzyme acts as a specialized cleanup crew, capable of neutralizing the toxic fats before they can destroy the cell membrane. Without enough of this enzyme, the cells succumb to a specific type of programmed death triggered by fat damage.

To test if boosting this enzyme could save the vision, the researchers turned to a mouse model of the disease. They used a harmless virus to deliver extra copies of the GPX4 gene directly into the retinal ganglion cells of the mice. They created two versions of the enzyme: one that stayed in the main body of the cell and another that was specifically guided into the mitochondria, the tiny power plants that generate energy for the cell. When the mice were subjected to the same blood-flow blockage that causes NAION, the results were striking. The mice that received the extra GPX4, particularly the version targeted to the mitochondria, retained far more of their retinal structure. Their nerve fibers remained thick and healthy, and their vision, measured by their ability to track moving patterns, was preserved. In contrast, the control mice lost significant amounts of nerve tissue and went blind. The study confirmed that simply increasing the amount of this cleanup enzyme was enough to stop the chain reaction of fat damage and keep the cells alive.

The researchers went further to understand exactly how this protection worked. Using advanced imaging techniques that allowed them to watch the cells in real time, they observed that the untreated mice suffered a catastrophic collapse in their cellular energy. Their mitochondria disappeared, their energy stores ran dry, and they were flooded with toxic stress signals. However, in the mice with the extra GPX4, the mitochondria remained abundant, the energy levels stayed high, and the toxic stress was kept in check. This suggests that the enzyme does more than just clean up fat; it keeps the entire energy system of the nerve cell running smoothly even under the extreme stress of a stroke. Furthermore, the researchers traced the connections from the eye to the brain and found that the treated mice maintained the vital pathways that carry visual information. The untreated mice lost these connections, severing the link between the eye and the brain, while the treated mice kept the line open, preserving the potential for sight.

Recognizing that gene therapy might be difficult to use for a sudden condition like NAION, where treatment must happen quickly after the event, the team looked for a drug that could mimic the action of the enzyme. They tested a small molecule called Ebselen, which has been studied in clinical trials for other conditions like stroke and hearing loss. Ebselen acts as a substitute for the GPX4 enzyme, performing the same fat-cleaning function. When the researchers gave Ebselen to mice shortly after inducing the stroke, it worked almost as well as the gene therapy. The drug prevented the fat damage, preserved the mitochondria, and maintained the visual connections to the brain. The treated mice retained their vision and the structural integrity of their optic nerves. This finding is significant because it suggests that a medication already known to be safe in humans could potentially be repurposed to treat NAION.

The study also clarified what does not cause the damage. While a similar type of cell death called ferroptosis is often linked to an overload of iron, the researchers found no significant increase in iron levels in the damaged optic nerves. This ruled out iron accumulation as the primary driver in this specific disease, pointing instead to the failure to detoxify the fats as the central problem. By isolating lipid peroxidation as the key mechanism, the researchers have provided a clear target for future therapies. The work demonstrates that the permanent vision loss seen in NAION is not an inevitable consequence of a blocked blood vessel, but rather a preventable cascade of chemical damage. By neutralizing the toxic fats with GPX4 or its mimics, it is possible to protect the nerve cells, maintain the energy they need to survive, and preserve the complex wiring that allows us to see. This approach offers a new path forward for a condition that currently has no effective treatment, turning a biological vulnerability into a solvable problem.